[Neytumorin as biomodular onco-therapy--allegations without documentation]
- PMID: 9244964
[Neytumorin as biomodular onco-therapy--allegations without documentation]
Abstract
NeyTumorin is a combination of peptides and proteins of 15 different organs from fetal and young pigs and cows. The list of indications ranges from cancer prevention to long-term treatment of malignancies. One vial of NeyTumorin-Sol costs DM 122.34. The therapy for a patient with a T1-2N0M0 cancer costs about DM 16,500 and an advanced stage up to over DM 100,000. The inventor of the Cytoplasmatic Therapy is K.E. Theurer. About 40 years ago, he founded the Vitorgan-Pharmaceutical Company which produces and distributes NeyTumorin. It is claimed that "physiological repair aids" from the cytoplasm of healthy animal organs induce a "hygiogenization" of the disturbed metabolism and NeyTumorin has immunogenic and immuno-modulatory effects which are important for the efficacy. The promotors classify NeyTumorin as a biological response modifier. The components of NeyTumorin are not defined. Preclinical investigations showing direct cytostatic and immunomodulatory effects are not sufficiently documented. Often extremely high concentrations of NeyTumorin were used. Clinical studies including prospective randomized trials are not conclusive because of false or insufficient documentation. There is no proof for either the claimed mechanism of action nor for a clinical efficacy.
Similar articles
-
[Factor AF2--the 4th column in tumor therapy. Documentation No.22].Schweiz Rundsch Med Prax. 1990 Apr 17;79(16):498-502. Schweiz Rundsch Med Prax. 1990. PMID: 2349412 German.
-
[New cytostatic drugs--indications and costs].Praxis (Bern 1994). 1999 Apr 29;88(18):791-801. Praxis (Bern 1994). 1999. PMID: 10409876 Review. German.
-
[Fever and chills following intravenous administration of NeyTumorin--an unconventional xenogenous derived peptides extract].Harefuah. 2002 May;141(5):433-4, 499. Harefuah. 2002. PMID: 12073521 Hebrew.
-
Outpatient cancer drug costs: changes, drivers, and the future.Cancer. 2002 Feb 15;94(4):1142-50. Cancer. 2002. PMID: 11920485
-
A clinical development paradigm for cancer vaccines and related biologics.J Immunother. 2007 Jan;30(1):1-15. doi: 10.1097/01.cji.0000211341.88835.ae. J Immunother. 2007. PMID: 17198079 Review.